<DOC>
	<DOCNO>NCT01052402</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity ( i.e . primary immune response , immunogenicity two different dos , antibody persistence 360 day first vaccination , immune response heterologous booster give Day 360 ) Vero cell-derived whole virus H5N1 influenza vaccine healthy infant , child adolescent age 6 month 17 year .</brief_summary>
	<brief_title>Safety Immunogenicity Study H5N1 Influenza Vaccine ( Vero Cell-Derived , Whole Virus ) Healthy Infants , Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>9 17 year age day screen ( Stratum A ) 3 8 year age day screen ( Stratum B ) 6 35 month age day screen ( Stratum C ) Subject bear full term pregnancy ( &gt; = 37 week ) birth weight &gt; = 2 kg ( Stratum C ) Subjects and/or parents/legal guardian understand nature procedure study agree provision Subjects´ parents/legal guardian provide write consent participation accord national law . In case parents/legal guardian illiterate , informed consent also sign independent witness Written assent accord subjects´ age capacity understanding Subjects generally healthy , determine investigator 's clinical judgment collection medical history performance physical examination Subjects physically mentally capable participate study follow procedure Subjects and/or parents/legal guardian agree keep daily record symptom duration study If subject female childbearing potential negative urine pregnancy test result within 24 hour prior schedule first vaccination agree employ adequate birth control measure duration study History exposure H5N1 virus history vaccination H5N1 influenza vaccine High risk contract H5N1 influenza infection ( e.g . contact poultry ) ; Subjects currently history significant neurological , cardiovascular , pulmonary ( include asthma ) , hepatic , metabolic , rheumatic , autoimmune , hematological renal disorder Inherited acquire immunodeficiency Subjects disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry expect influence immune response . Such treatment include , limited , systemic high dose inhale corticosteroid , radiation treatment immunosuppressive cytotoxic drug . History severe allergic reaction anaphylaxis Rash , dermatological condition tattoo may interfere injection site reaction rating Subjects receive blood transfusion immunoglobulin within 90 day prior study entry Subjects receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study Functional surgical asplenia Subjects know suspect problem alcohol drug abuse Subjects administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product Dependent relationship study site personnel . Dependent relationship include close relative ( i.e. , child , sibling ) . If female : subject wo pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>